The Innovative Medtech Giant AMS Reveals Total Voting Rights Amidst Steady Expansion

Advanced Medical Solutions Group (AMS), a world-renowned medical technology company, based in the UK, has revealed its total voting rights, according to the Disclosure and Transparency Rule 5.6.1. As of 31st March 2025, the company’s issued share capital comprises 217,994,699 ordinary shares of 5p each with full voting rights. In a reassuring note to its investors, AMS confirmed that no shares are held in treasury.

This announcement comes during a key period of growth for the company, which has been aggressively expanding its international footprint and portfolio. Notably, since 2019, the group has made seven strategic acquisitions, including Sealantis, an Israeli developer of internal sealants, Biomatlante, a French surgical biomaterial developer, and Raleigh, a UK-based wound care and bio-diagnostic materials manufacturer.

The company’s global outreach is supported by a network of multinational partners and distributors as well as its own direct sales forces. Its formidable R&D strength is spread across innovation hubs in the UK, Ireland, Germany, France, and Israel. Since its establishment in 1991, the company has grown to employ over 1,500 people across the globe, ensuring the constant evolution of its product lines and medical practices worldwide.